Alberto Vitari, PhD has extensive and diverse experience driving and delivering target identification and validation projects. Proficient in cancer genomics, functional genetics and leveraging bioinformatics tools to identify novel targets that serve as a basis for drug development projects.
Before joining full time Rubedo Life Sciences, he was Group Leader, Molecular and Cellular Biology at Verily (formerly Google Life Sciences)
Former Group Leader at Novartis Institutes for BioMedical Research
Responsible for the identification of novel molecular targets to cure cancer for Novartis drug discovery projects; his expertise is in cell signaling, cancer genetics and target identification and mechanism of action of pre-clinical drug candidates; integrating data to provide guidance to patient selection.
He also served as a postdoctoral Scientist at Genentech in USA and at Pharmacy Corporation in Italy.
His scientific record includes top tier publications (in Cell, Science and Nature), including a seminal work on proto-oncogenic factors (Vitari et al., Nature, 2011).